Bio-link Australia Pty. Ltd.

Team

The Bio-Link Team, located in our Melbourne and Sydney offices, consist of two executive directors, complemented by talented employees and interns, who work together to provide professional, cost effective and transparent services to our clients.

Bio-Link team photo
From Left: Poornima Ravi, Oliver Croad, Christopher Boyer, Gorjana Mitic, Karen Li, Andrew Coley, Christian Toouli
(Absent: Perdita Cheshire, Lieven Huang, Lilly Bojarski and Aislinn Treolar)

Mr Christopher Boyer - Executive Director

Christopher specialises in the selling of biotechnology, as the culmination of his 20+ year career spanning its discovery, development and commercialisation. Most recently, as Executive Director of Bio-Link, Christopher led licensing efforts for a range of drug and diagnostic opportunities and closed several deals.

Prior to joining Bio-Link, Christopher served as Business Development Manager at Cryptome Pharmaceuticals, a peptide therapeutics developer in Melbourne. Earlier he was Manager, Corporate and Strategic Development at NewBiotics, a San Diego drug developer, where he negotiated contracts and contributed to a $20M co-development deal for cancer chemotherapeutics. Christopher also consulted to San Diego’s Halozyme Therapeutics, a developer of therapeutic enzymes, preparing project valuations to support a successful $9.2M Series A financing.

Christopher draws upon deep technical insights acquired during his extensive R&D experience in small molecule drug discovery and molecular neuroscience, attained at Novartis and the Howard Hughes Medical Institute respectively. He earned a BS in Animal Physiology and Neuroscience from the University of California, San Diego, and augmented his business skills with an MBA in Marketing from the University of San Diego.



Dr Christian Toouli - Executive Director

Christian is a motivated and resourceful Commercialisation Executive, dedicated to identifying, developing and generating value from biotechnology intellectual property.

As Co-Founder and Executive Director of Bio-Link Australia, Christian has worked with many of the company’s Australian and international drug discovery and development clients. Accessing a large network of contacts from throughout the global biopharmaceutical industry, and with broad business development, project management and scientific expertise, he has facilitated numerous technology evaluation, IP licensing and partnering deals with international life sciences and biopharmaceutical companies.

Previously, Christian was a Postdoctoral Fellow in the Discovery Research Department of Schering-Plough Biopharma/DNAX Research Institute, the biotechnology arm of Schering-Plough Corporation. In this capacity, he investigated novel targets for oncology therapeutics and undertook competitive intelligence analyses for senior management.

During this time, Christian also served as the United States National and San Francisco Regional Life Sciences Co-Chair for Advance, the Australian expatriate professional network in the United States. Christian received his PhD from the University of Sydney for his research into cellular immortalisation and telomere maintenance at the Children’s Medical Research Institute. He was awarded a Certificate in Biotechnology Management with Honours from the University of California, Santa Cruz Extension, and First-Class Honours in Biotechnology from Flinders University of South Australia. Christian is also a graduate of the Australian Institute of Company Directors.



Dr Andrew Coley - Biotechnology Advisor

Andrew is a specialist in the development and commercialisation of early-stage biotechnology and drug development programs. His career has spanned diagnostic pathology, academic research, and biotechnology executive management. Andrew qualified in medical science/pathology, specialising in medical microbiology. He has held positions in the Diagnostic Pathology department at Bedford General Hospital, UK; and Gastroenterology at Addenbrookes Hospital, UK.

Andrew was appointed Chief Scientific Officer at TransBio Ltd. in 2007, a position he held for seven years. His roles at the company included oversight of the cancer and autoimmunity biomarker research portfolio, project management, intellectual property management and licencing. He is currently a member of the editorial board of Cell Biology Insights and the NHMRC Translational Research Faculty.

Andrew received his PhD in Immunology and Cell Biology at the Clinical Sciences Centre and Royal Postgraduate Medical School, University College London, followed by ten years’ academic research as a Research Fellow in Immunology and Vaccine Development at La Trobe University, Melbourne.



Dr Gorjana Mitic - Senior Business Development Associate

Gorjana joined our Sydney team after completing the company’s internship program. As a Senior Business Development Associate, Gorjana strategically reviews clients’ technologies for commercial potential, conducts proactive business development campaigns and engages with prospective partners to achieve optimal outcomes for Bio-Link’s clients (biotechnology and pharmaceutical companies and Medical Research Institutes). Her additional responsibilities include commercialisation strategy development and consulting services such as comprehensive reviews of regulatory, competitive and IP landscapes.

Prior to receiving her PhD at the Children’s Cancer Institute from the University of New South Wales (UNSW) Faculty of Medicine, Gorjana completed a Bachelor of Biotechnology with First-Class Honours at UNSW. Her PhD thesis investigated new molecular targets in glioblastoma, a devastating brain cancer, focusing on components of the cellular cytoskeleton. In 2013, Gorjana was awarded a prestigious Women in Cancer Research Scholar Award.

Concurrently, Gorjana obtained a Diploma of Innovation Management at UNSW focusing on the biotechnology industry, science commercialisation, technology transfer and IP management. She served as an active committee member and a UNSW student representative of the AusBiotech Student Association. In these roles, she successfully coordinated numerous workshops and events with prominent industry speakers.



Dr Perdita Cheshire - Business Development Associate

Perdita has experience in commercialisation and technology transfer gained through industry internships including the Molecules to Medicines program. Perdita brings additional experience and formal training in quality and regulatory affairs as well as GMP and GCP compliance.

Perdita’s post-doctoral research developing cell therapies for the treatment of burn injuries in the Victorian Adult Burns Service, Alfred Hospital, exemplifies her expertise in translating research across in vitro, in vivo, manufacturing and clinical trial platforms.

Originally from the UK, Perdita completed her undergraduate degree in Neuroscience at the University of Sussex before moving into the field of artificial life and computational neuroscience during her Master’s degree. After working at University College London, Perdita moved to Melbourne where she completed her PhD in neuroscience through Monash University at the Alfred Hospital.



Dr Lieven Huang - Business Development Associate

Lieven is enthusiastic about the translation of basic research into real-life applications. He is keen to drive commercialisation of scientific innovations for the benefit of human health and to boost the biopharmaceutical industry in Australia.

Prior to working for Bio-Link, Lieven completed a postdoc at the Australian Regenerative Medicine Institute (ARMI, Monash University) where he investigated the regenerative capacity of brain’s cerebral cortex. Lieven also spent 4 years in the UK as an MRC Career Development Fellow at Imperial College London studying structural plasticity in the brain via in vivo two-photon microscopy in the context of sensory experience, aging and axonal damage.

Lieven obtained his PhD from the Universities of Brussels (VUB) and Ghent (UGent) in Belgium in the field of Applied Immunology. For his research he collaborated with biotech company Ablynx for the development of cancer-targeting Nanobodies. His work also resulted in a successful patent application after discovering the anti-tumour effects of a novel recombinant protein. While completing his Master’s Degree in Bio-engineering, Lieven developed a surface acoustic wave-based biosensor to help diagnose prostate cancer. This research was conducted at the internationally renowned Imec Institute in Leuven.



Dr Lilly Bojarski - Business Development Associate

Lilly received a Bachelor of Science and Masters of Science degrees in toxicology from the University of Guelph, in Canada, prior to moving to New Zealand where she completed a cross-disciplinary PhD at the University of Auckland. Her thesis research addressed questions of nutritional chemistry, bacterial genetics, gut microbiome structure and function, and microbial metagenomics. Between the Bachelors and Masters degrees she was introduced to scientific commercialisation whilst working as a visiting scientist at AgResearch, a Crown Research Institute in New Zealand.

After completing the Bio-Link Internship Program Lilly has continued to work as a Business Development Associate, working with management to conduct IP and competitor landscape surveys, producing commercial opportunity summaries and other reports, and working with clients. While not at Bio-Link, Lilly is involved in conducting fundamental studies of gene regulation using emerging next-generation sequencing technologies at the Garvan Institute of Medical Research, and manages the busy lab of its Director.



Ms Aislinn Treloar - Business Development Associate

Aislinn has a passion for integrating medical technology and business processes. She uses her research expertise as a foundation to deliver relevant and strategic solutions to businesses that are striving to bring innovative therapeutics to market.

Aislinn obtained a Masters of Science from the University of Toronto’s Department of Medical Biophysics, in Canada. Her research focused on identifying the functional epigenetic mechanisms underlying cancer progression. This work exploited the dependence of breast cancer cells on interactions between non-coding regulatory elements in the genome to suppress their response to hormonal stimulation and dampen their growth. Prior to her Masters Degree studies, Aislinn received a Bachelor of Arts and Science, Economics and Molecular Biology from McGill University in Montreal, Canada.